Urogastrone and Epidermal Growth Factor

Gregory, H.; Bower, James M.; Willshire, I. R.

doi:10.1016/b978-0-08-022629-3.50014-3

Cited by 19 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The peptide also acts on isolated gastric mucosal preparations and has a beneficial effect on experimentally induced ulcers (Gregory, 1977). In addition, urogastrone stimulates DNA synthesis and the uptake of amino acids by cultured skin fibroblasts (Hollenberg and Gregory, 1976) and is stable to proteolytic enzymes such as trypsin, chymotrypsin, and pepsin (Gregory and Preston, 1977).…”

Section: Resultsmentioning

confidence: 99%

Immunohistochemical localisation of urogastrone to human duodenal and submandibular glands.

Heitz¹,

Kasper²,

Noorden³

et al. 1978

Gut

198

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Immunohistochemical localisation of urogastrone to human duodenal and submandibular glands.

Heitz¹,

Kasper²,

Noorden³

et al. 1978

Gut

198

View full text Add to dashboard Cite

“…[1][2][3][4][5][6]. The recognized biological actions of EGF-URO are stimulation of cellular proliferation and inhibition of gastric acid secretion; in addition, the occurrence of receptors for EGF-URO in a large number of tissues, including the placenta (6,7), and the effects of EGF-URO observed in organ cultures on the secondary palatal epithelium (8,9) suggest that EGF-URO plays an important role in embryonic development.…”

mentioning

confidence: 99%

Detection of epidermal growth factor-urogastrone and its receptor during fetal mouse development

Nexø

Hollenberg

Figueroa

et al. 1980

Proc. Natl. Acad. Sci. U.S.A.

162

View full text Add to dashboard Cite

Using both a radioimmunoassay and a radioreceptor assay, we have estimated the content of mouse epidermal growth factor-urogastrone (EGF-URO) in fetal mice at 111/2 to 171/2 days of gestation. Concurrently, the amount of specific EGF-URO receptor binding was determined in crude membrane fractions from the embryos. EGF-URO receptor binding is readily detected in membranes from the youngest embryos (day 11/2) and rises steadily up to parturition (18 days); the rise is more marked in embryo membranes derived from a potential target tissue, such as the maxilla and secondary palate. In the embryonic extracts, EGF-URO proved to be labile, requiring the presence of soybean trypsin inhibitor and sodium azide to stabilize the recovery of added EGF-URO in test samples. Even with added stabilizing agents, immunoreactive EGF-URO was barely detectable before day 141/2 (less than 20 fmol per embryo), whereas a substantial increase was observed from day 151/2 to 171/2 (from 70 to 200 fmol per embryo). In contrast, the radioreceptor assay detected appreciable amounts of an EGF-URO-like substance at 111/2 days (50 fmol per embryo) the values estimated by radioreceptor assay (about 0 old higher than by radioimmunoassay) also increase markedly between days 151/2 and 171/2 (on average from 500 to 3000 fmol per embryo). We conclude that during fetal mouse development there is an increase both in the receptors for EGF-URO and in a substance (presumably a fetal growth factor) that can occupy the receptor. The differences between the radioreceptor and radioimmunoassay estimates for the EGF-URO content suggest that the fetal form of mouse EGF-URO differs from the a ult molecule.Epidermal growth factor-urogastrone (EGF-URO) is a polypeptide of approximately 6000 daltons that is found in mice, in humans, and undoubtedly in a variety of other mammalian species (for reviews, see refs. 1-6). The recognized biological actions of EGF-URO are stimulation of cellular proliferation and inhibition of gastric acid secretion; in addition, the occurrence of receptors for EGF-URO in a large number of tissues, including the placenta (6, 7), and the effects of EGF-URO observed in organ cultures on the secondary palatal epithelium (8,9) suggest that EGF-URO plays an important role in embryonic development. Although the time course of the postnatal accumulation of EGF-URO in male mice has been observed [the submaxillary gland content rises to a maximum at about 50 days (10)], no detailed studies have been made in prenatal animals. Because of our interest in the effects of EGF-URO on palatal development, we have determined the content of both EGF-URO and its receptor at various stages of development. We have used both a radioreceptor and a radioimmunoassay to measure increasing levels of EGF-URO in embryos at 11/2 to 171/2 days of gestation, and we have concurrently measured increases in EGF-URO binding in membranes obtained from embryos at 12 to 14 days of gestation. MATERIALS AND METHODSPolypeptides and Antibodies. Mouse EGF-URO was either isolat...

show abstract

“…However, the changes observed were also less than twofold. The results suggest a stringent regulation of low levels of serum EGF and a rapid clearance by other organs (205,256).…”

Section: Absorption Of Egf In Vivomentioning

confidence: 87%